GC= Audi

'99 A6 QUATTRO LEASE SPECIAL

3-Year/50,000 Mile Maintenance Included

ce

The following Internet sites can provide additional information about breast
cancer:
nsabp.pitt.edu The National Surgical Adjuvant Breast and Bowel Project.
med.jhu.eduibreastcentedresearchistar.html Johns Hopkins STAR information
cancertrials.nci.nih.gov. The National Cancer Institute Clinical Trials

r?

----- -

.\•, , ZI

'495*

$1800 due at signing

•

BOSE Audio, 16 inch wheels,
cold weather package,convenience
package, leather, loaded.

*36 mos. lease based on approved credit. 12,000 miles,
$1800 due at signing, plus tax, title, plate and sec. dep.

L

Co=

Audi

The Areal. Largest Selection ofAudis

Mon. & Thurs. 9-9, Wed:A Fri 9-6
www.billcookauto.com
37911 Grand River • Farmington Hills

(248) 471-0800

experience the Magic

ALL ABOUT

CRUISES
INCORPORATED

AMERICA'S AWARD WINNING CRUISE AGENCY

2 for 1 Cruise SPECIALS...20-70%

ON 1999 CRUISES!

All Destinations • All Dates

•Senior Discounts*

AMERICA • EUROPE • ALASKA • PANAMA CANAL
SOUTH AMERICA
• • CARIBBEAN

cede

to for AU

yoga frayed moods!

1-800-343-8970

http://www.allaboutcruises.com

•

LEARNING
DISABILITIES
CLINIC

• Clinical acititt
♦ Tizerai)eutic

stina/Evaluation

7/Ito/ging

(248)545-.6677 • (248)433-3323

LYNNE MASTER, M .Ed

8/27

1999

Owner, Director

116 Detroit Jewish News

Oak Park

Bloomfield Hills

reww.lciclinic.corn

Cancer Institute and an
associate professor of
medicine and oncology
at Wayne State
University He feels
strongly that STAR
could become a land-
mark study in cancer
prevention.
"Along with cancer
detection and treat-
ment, enhanced pre-
vention techniques are
helping us more effec-
tively battle cancer,"
Dr. Judie Goodman talks to Dale Shaham of West
said Dr. Simon. "Our
Bloomfield about the STAR study.
goal is to determine
whether raloxifene is
either more or less
receive either 20 mg tamoxifen or 60
effective than tamoxifen in reducing
mg raloxifene daily for five years. She
the incidence of invasive breast can-
will have regular follow-up examina-
cer in postmenopausal women who
tions, including mammograms and
are at increased risk for the disease."
gynecologic exams.
He said patients for the trial must
Each participant also is given a place-
meet a strict set of eligibility rules.
bo to look like the other medication, so
Women must be postmenopausal, at
the participant will not know which
least age 35, and have an increased risk
medication she has been assigned.
of breast cancer as determined by their
"There is no better way to attack this
age, family history of breast can c er, per-
cancer than to prevent it in the first
sonal medical history, age at first men-
place," said Dr. Simon. And these two
strual period, and age at first live birth.
drugs have demonstrated potential to
STAR clinical study is limited to
do that. Tamoxifen is a medically
postmenopausal women because the
proven intervention, but it's not perfect.
drug raloxifene has not been adequately
Women who are at an increased risk of
tested for long-term safety in pre-
breast cancer need options for prevent-
menopausal women.
ing this disease with a minimum of side
Each candidate for the study goes
effects and STAR is making the effort
through an informed-consent process,
to find one."
learning about the potential benefits
and risks of the two drugs before
STAR And Jewish Genetics
deciding whether to participate.
The STAR clinical trial does not
Women diagnosed as having lobu-
specifically address how the compari-
lar carcinoma in situ, a condition that
son directly impacts women of
is not canter but indicates an
Ashkenazi Jewish descent who know
increased chance of developing inva-
they carry the BRCA mutations linked
sive breast cancer, are eligible on that
to breast cancer.
diagnosis alone.
What is known, however, is that
•Women taking hormone replacement
the
Jewish population of Ashkenazi
therapy (estrogen or an estrogen/proges-
descent
— both men and women —
terone combination) cannot take part in
is
at
higher
risk for a number of can-
the trial unless they stop taking these
cers
including
breast, ovarian and col-
medications. Women with a history of
orectal.
"Forty
to 80 percent of carri-
cancer, blood clots, stroke, heartbeat
ers
of
genetic
mutations
in BRCA I or
irregularities, high blood pressure and
BRCA
2
will
develop
cancer,"
said
diabetes also are not eligible.
chief
scientif-
Ph.D.,
Michael
Tainsky,
Once a woman chooses to partici-
ic officer and director of programs in
pate, she is randomly assigned to